Leo A B Joosten1, Tania O Crişan2, Tania Azam3, Maartje C P Cleophas2, Marije I Koenders4, Frank L van de Veerdonk2, Mihai G Netea2, Soohyun Kim5, Charles A Dinarello1. 1. Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands Radboud Institute of Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, The Netherlands. 2. Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands Radboud Institute of Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, The Netherlands. 3. Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA. 4. Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands. 5. Laboratory of Cytokine Immunology, Konkuk University, Seoul, Korea.
Abstract
OBJECTIVES: In the present study, we generated a new protein, recombinant human alpha-1-anti-trypsin (AAT)-IgG1 Fc fusion protein (AAT-Fc), and evaluated its properties to suppress inflammation and interleukin (IL)-1β in a mouse model of gouty arthritis. METHODS: A combination of monosodium urate (MSU) crystals and the fatty acid C16.0 (MSU/C16.0) was injected intra-articularly into the knee to induce gouty arthritis. Joint swelling, synovial cytokine production and histopathology were determined after 4 h. AAT-Fc was evaluated for inhibition of MSU/C16.0-induced IL-1β release from human blood monocytes and for inhibition of extracellular IL-1β precursor processing. RESULTS: AAT-Fc markedly suppressed MSU/C16.0-induced joint inflammation by 85-91% (p<0.001). Ex vivo production of IL-1β and IL-6 from cultured synovia were similarly reduced (63% and 65%, respectively). The efficacy of 2.0 mg/kg AAT-Fc in reducing inflammation was comparable to 80 mg/kg of plasma-derived AAT. Injection of AAT-Fc into mice increased circulating levels of endogenous IL-1 receptor antagonist by fourfold. We also observed that joint swelling was reduced by 80%, cellular infiltration by 95% and synovial production of IL-1β by 60% in transgenic mice expressing low levels of human AAT. In vitro, AAT-Fc reduced MSU/C16.0-induced release of IL-1β from human blood monocytes and inhibited proteinase-3-mediated extracellular processing of the IL-1β precursor into active IL-1β. CONCLUSIONS: A single low dose of AAT-Fc is highly effective in reducing joint inflammation in this model of acute gouty arthritis. Considering the long-term safety of plasma-derived AAT use in humans, subcutaneous AAT-Fc emerges as a promising therapy for gout attacks. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: In the present study, we generated a new protein, recombinant human alpha-1-anti-trypsin (AAT)-IgG1 Fc fusion protein (AAT-Fc), and evaluated its properties to suppress inflammation and interleukin (IL)-1β in a mouse model of gouty arthritis. METHODS: A combination of monosodium urate (MSU) crystals and the fatty acid C16.0 (MSU/C16.0) was injected intra-articularly into the knee to induce gouty arthritis. Joint swelling, synovial cytokine production and histopathology were determined after 4 h. AAT-Fc was evaluated for inhibition of MSU/C16.0-induced IL-1β release from human blood monocytes and for inhibition of extracellular IL-1β precursor processing. RESULTS:AAT-Fc markedly suppressed MSU/C16.0-induced joint inflammation by 85-91% (p<0.001). Ex vivo production of IL-1β and IL-6 from cultured synovia were similarly reduced (63% and 65%, respectively). The efficacy of 2.0 mg/kg AAT-Fc in reducing inflammation was comparable to 80 mg/kg of plasma-derived AAT. Injection of AAT-Fc into mice increased circulating levels of endogenous IL-1 receptor antagonist by fourfold. We also observed that joint swelling was reduced by 80%, cellular infiltration by 95% and synovial production of IL-1β by 60% in transgenic mice expressing low levels of humanAAT. In vitro, AAT-Fc reduced MSU/C16.0-induced release of IL-1β from human blood monocytes and inhibited proteinase-3-mediated extracellular processing of the IL-1β precursor into active IL-1β. CONCLUSIONS: A single low dose of AAT-Fc is highly effective in reducing joint inflammation in this model of acute gouty arthritis. Considering the long-term safety of plasma-derived AAT use in humans, subcutaneous AAT-Fc emerges as a promising therapy for gout attacks. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Andreea-Manuela Mirea; Cees J Tack; Triantafyllos Chavakis; Leo A B Joosten; Erik J M Toonen Journal: Trends Mol Med Date: 2018-04-14 Impact factor: 11.951
Authors: Rob Ter Horst; Martin Jaeger; Sanne P Smeekens; Marije Oosting; Morris A Swertz; Yang Li; Vinod Kumar; Dimitri A Diavatopoulos; Anne F M Jansen; Heidi Lemmers; Helga Toenhake-Dijkstra; Antonius E van Herwaarden; Matthijs Janssen; Renate G van der Molen; Irma Joosten; Fred C G J Sweep; Johannes W Smit; Romana T Netea-Maier; Mieke M J F Koenders; Ramnik J Xavier; Jos W M van der Meer; Charles A Dinarello; Norman Pavelka; Cisca Wijmenga; Richard A Notebaart; Leo A B Joosten; Mihai G Netea Journal: Cell Date: 2016-11-03 Impact factor: 41.582
Authors: Tania O Crişan; Maartje C P Cleophas; Boris Novakovic; Kathrin Erler; Frank L van de Veerdonk; Hendrik G Stunnenberg; Mihai G Netea; Charles A Dinarello; Leo A B Joosten Journal: Proc Natl Acad Sci U S A Date: 2017-05-08 Impact factor: 11.205
Authors: Mihai G Netea; Frances Balkwill; Michel Chonchol; Fabio Cominelli; Marc Y Donath; Evangelos J Giamarellos-Bourboulis; Douglas Golenbock; Mark S Gresnigt; Michael T Heneka; Hal M Hoffman; Richard Hotchkiss; Leo A B Joosten; Daniel L Kastner; Martin Korte; Eicke Latz; Peter Libby; Thomas Mandrup-Poulsen; Alberto Mantovani; Kingston H G Mills; Kristen L Nowak; Luke A O'Neill; Peter Pickkers; Tom van der Poll; Paul M Ridker; Joost Schalkwijk; David A Schwartz; Britta Siegmund; Clifford J Steer; Herbert Tilg; Jos W M van der Meer; Frank L van de Veerdonk; Charles A Dinarello Journal: Nat Immunol Date: 2017-07-19 Impact factor: 25.606
Authors: Dennis M de Graaf; Ralph J A Maas; Sanne P Smeekens; Elan Eisenmesser; Jasmina S Redzic; Monique M Helsen; Nicholas E Powers; Suzhao Li; Vassili Kalabokis; Mark S Gresnigt; Leo A B Joosten; Charles A Dinarello; Frank L van de Veerdonk Journal: Cytokine Date: 2020-10-28 Impact factor: 3.861